{
    "address1": "855 North Wolfe Street",
    "address2": "Suite 601",
    "city": "Baltimore",
    "state": "MD",
    "zip": "21205",
    "country": "United States",
    "phone": "(856) 848-8698",
    "website": "https://www.mymd.com",
    "industry": "Biotechnology",
    "industryDisp": "Biotechnology",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.",
    "fullTimeEmployees": 9,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Dr. Christopher C. Chapman Jr., M.D.",
            "age": 69,
            "title": "Pres, Chief Medical Officer & Director",
            "yearBorn": 1953,
            "fiscalYear": 2022,
            "totalPay": 261827,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Adam  Kaplin M.D., Ph.D.",
            "age": 55,
            "title": "Chief Scientific Officer",
            "yearBorn": 1967,
            "fiscalYear": 2022,
            "totalPay": 353733,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Paul M. Rivard Esq.",
            "age": 51,
            "title": "Chief Legal Officer",
            "yearBorn": 1971,
            "fiscalYear": 2022,
            "totalPay": 188239,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Ian  Rhodes CPA",
            "age": 49,
            "title": "Interim Chief Financial Officer",
            "yearBorn": 1973,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. Jenna  Brager M.S., Ph.D., R.N.",
            "title": "Exec. VP of Drug Devel.",
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 4,
    "previousClose": 1.13,
    "open": 1.14,
    "dayLow": 1.01,
    "dayHigh": 1.1492,
    "regularMarketPreviousClose": 1.13,
    "regularMarketOpen": 1.14,
    "regularMarketDayLow": 1.01,
    "regularMarketDayHigh": 1.1492,
    "payoutRatio": 0.0,
    "beta": 4.03749,
    "volume": 674669,
    "regularMarketVolume": 674669,
    "averageVolume": 721445,
    "averageVolume10days": 478490,
    "averageDailyVolume10Day": 478490,
    "bid": 1.05,
    "ask": 1.1,
    "bidSize": 4000,
    "askSize": 1000,
    "marketCap": 47626220,
    "fiftyTwoWeekLow": 0.8,
    "fiftyTwoWeekHigh": 3.93,
    "fiftyDayAverage": 1.29572,
    "twoHundredDayAverage": 1.6711,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "enterpriseValue": 37014016,
    "profitMargins": 0.0,
    "floatShares": 37566298,
    "sharesOutstanding": 44930400,
    "sharesShort": 2741424,
    "sharesShortPriorMonth": 3535618,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.061,
    "heldPercentInsiders": 0.17254,
    "heldPercentInstitutions": 0.107480004,
    "shortRatio": 2.36,
    "shortPercentOfFloat": 0.0614,
    "impliedSharesOutstanding": 44930400,
    "bookValue": 0.252,
    "priceToBook": 4.206349,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "netIncomeToCommon": -13650773,
    "trailingEps": -0.33,
    "lastSplitFactor": "1:2",
    "lastSplitDate": 1618790400,
    "52WeekChange": -0.69186044,
    "SandP52WeekChange": 0.09306288,
    "exchange": "NCM",
    "quoteType": "EQUITY",
    "symbol": "MYMD",
    "underlyingSymbol": "MYMD",
    "shortName": "MyMD Pharmaceuticals, Inc.",
    "longName": "MyMD Pharmaceuticals, Inc.",
    "firstTradeDateEpochUtc": 1390487400,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "34173f06-54fb-3bb0-ac22-953c9b18b337",
    "messageBoardId": "finmb_694917951",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 1.06,
    "recommendationKey": "none",
    "totalCash": 11627255,
    "totalCashPerShare": 0.259,
    "totalDebt": 109792,
    "quickRatio": 4.787,
    "currentRatio": 5.411,
    "debtToEquity": 0.955,
    "returnOnAssets": -0.42578,
    "returnOnEquity": -0.94991,
    "freeCashflow": -7869188,
    "operatingCashflow": -14227340,
    "grossMargins": 0.0,
    "ebitdaMargins": 0.0,
    "operatingMargins": 0.0,
    "financialCurrency": "USD",
    "trailingPegRatio": null,
    "parent_etfs": [
        "POTX"
    ]
}